Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A
AMPK/SIRT1
Cyclosporin A
Hypertension
Resveratrol
Thromboxane A(2) receptor
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
19
01
2024
revised:
14
03
2024
accepted:
26
03
2024
medline:
7
4
2024
pubmed:
7
4
2024
entrez:
6
4
2024
Statut:
aheadofprint
Résumé
Cyclosporin A, an immunosuppressive agent, is extensively utilized for the prevention of transplant rejection and treat autoimmune disease in the clinic, despite its association with a high risk of hypertension development among patients. Resveratrol is a kind of non-flavonoid phenolic compound that widely exists in many plants. The aim of the present study was to investigate the mechanism by which resveratrol ameliorates cyclosporin A-induced hypertension. The arterial rings of the mesentery were incubated with cyclosporin A and resveratrol in vitro. Rats were administered cyclosporin A and/or resveratrol for 3 weeks in vivo. Blood pressure was measured via the tail arteries. Vasoconstriction curves were recorded using a sensitive myograph. The protein expression was evaluated through Western blotting. This study demonstrated that resveratrol mitigated the cyclosporin A-induced increase in blood pressure in rats. Furthermore, resveratrol markedly inhibited the cyclosporin A-induced upregulation of thromboxane A
Identifiants
pubmed: 38582274
pii: S0014-2999(24)00231-0
doi: 10.1016/j.ejphar.2024.176543
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176543Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest All the authors declare that they have no conflicts of interest.